• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human IGFBP-4 protein (His Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 0.025-0.1µg/mL

Cat no : Eg0825

Validation Data Gallery

  • Purity of Recombinant Human IGFBP-4 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human IGFBP-4 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

  • Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. The EC50 for this effect is 0.025-0.1µg/mL in the presence of 30 ng/mL Recombinant Human IGF-I.

    Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. The EC50 for this effect is 0.025-0.1µg/mL in the presence of 30 ng/mL Recombinant Human IGF-I.

Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. The EC50 for this effect is 0.025-0.1µg/mL in the presence of 30 ng/mL Recombinant Human IGF-I.
Expression HEK293-derived Human IGFBP-4 protein Asp22-Glu258 (Accession# P22692-1) with a His tag at the C-terminus.
GeneID 3487
Accession P22692-1
PredictedSize 26.8 kDa
SDS-PAGE 27-32 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IGFBP4, also named as IBP4, is a 258 amino acid protein, which contains one IGFBP N-terminal domain and one thyroglobulin type-1 domain. IGFBP4 is the smallest member of the insulin-like growth factor binding protein family (IGFBP). It is a hepatic protein that plays a role in modulating the activity and bioavailability of IGF-I. The expression of IGFBP4 was found to increase under conditions of hypoxia. IGFBP4 is highly expressed in adipocytes and osteoblasts and is inhibitory of IGFs in vitro.

References:

1.Maridas, David E et al. (2017). Endocrinology. 158(10):3488-3500. 
2.Alterki, Abdulmohsen et al. (2021). Disease markers.1219593.
3.Ruan, Peng et al. (2023). Cell Biol Toxicol. 39(4):1611-1626.